BLA 125288 · Bristol Myers Squibb
Nulojix
Belatacept · Injection · Selective T Cell Costimulation Blocker
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jul 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jun 15, 2011
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
69
8 Phase 3, 9 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Belatacept" as an intervention, any sponsor and status, largest first.
- Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)Pivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00256750 · 738 participants · Start Mar 2005 · Primary completion Jun 2008
Drug: Cyclosporine (CsA); Belatacept LI (less intensive) and 1 more · For: Kidney Transplantation; Chronic Kidney Failure
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 105 sites in all
- Study of Belatacept in Subjects Who Are Undergoing a Renal TransplantPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00114777 · 595 participants · Start Feb 2005 · Primary completion May 2008
Drug: Cyclosporin A; Belatacept Less Intensive Regimen (LI) and 1 more · For: Renal Transplantation
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 79 sites in all
- A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process CPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02564497 · 491 participants · Start Oct 2, 2015 · Primary completion Jan 27, 2017
Drug: Process E Belatacept; Process C Belatacept · For: Renal Transplantation
Sites: Austin, Texas
- A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-BasedPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01820572 · 446 participants · Start Mar 27, 2013 · Primary completion Oct 24, 2019
Drug: Belatacept; Tacrolimus and 1 more · For: Kidney Transplantation
Sites: Birmingham, Alabama; Phoenix, Arizona; Loma Linda, California · 117 sites in all
- Belatacept Early Steroid Withdrawal TrialPivotal-lookingCompleted
University of CincinnatiAcademic, hospital or other
NCT01729494 · 316 participants · Start Sep 2012 · Primary completion Dec 2018
Drug: Alemtuzumab; rabbit antithymocyte globulin and 4 more · For: Renal Transplantation
Sites: San Francisco, California; Denver, Colorado; Tampa, Florida · 8 sites in all
- Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)Pivotal-lookingNot yet recruiting
University Hospital, RouenAcademic, hospital or other
NCT06291103 · 290 participants (planned) · Start Jul 1, 2026 · Primary completion Aug 1, 2032
Drug: Conversion to Belatacep; Standard of care treatment (SOC regimen) with Tacrolimus · For: Kidney Transplant Rejection
Sites: Rouen, France
- Belatacept in Liver Transplant RecipientsPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00555321 · 260 participants · Start Jan 2008 · Primary completion Mar 2010
Drug: Tacrolimus; Basiliximab and 3 more · For: Immunosuppression in Solid Organ Transplant
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 42 sites in all
- Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted KidneyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00035555 · 230 participants · Start Mar 2001 · Primary completion Jan 2004
Drug: Belatacept; Cyclosporine and 2 more · For: Graft Rejection; Kidney Transplantation; Renal Transplantation
Sites: San Francisco, California; Atlanta, Georgia; Baltimore, Maryland · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nulojix (Belatacept)
2024 spending
$5.4M
Beneficiaries
289
2,399 claims
Per beneficiary
$18,513
$911.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,112,483 |
| 2021 | $6,413,170 |
| 2022 | $5,809,349 |
| 2023 | $5,270,868 |
| 2024 | $5,350,186 |
Part B: Nulojix (Belatacept) · HCPCS J0485
2024 spending
$122M
Beneficiaries
6,789
60,375 claims
Per beneficiary
$18,009
2024 ASP limit $3.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $62,801,186 |
| 2021 | $74,281,399 |
| 2022 | $93,760,191 |
| 2023 | $107,204,978 |
| 2024 | $122,265,211 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, et al. · Am J Transplant 2010 · Clinical Trial, Phase III, Multicenter Study
- Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K, Prashar R, Haller H, et al. · J Am Soc Nephrol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients.
Efe O, Al Jurdi A, Eiting MM, et al. · Front Immunol 2024 · Multicenter Study, Clinical Trial, Phase II
- Belatacept rescue therapy of CNI-induced nephrotoxicity, meta-analysis.
El Hennawy H, Safar O, Al Faifi AS, et al. · Transplant Rev (Orlando) 2021 · Meta-Analysis, Review
- Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients.
Tawhari I, Hallak P, Bin S, et al. · Front Immunol 2022 · Randomized Controlled Trial
- Dual targeting of B cell compartments using belatacept and daratumumab in highly sensitized kidney transplant candidates: A mechanistic proof-of-concept desensitization trial.
Malvezzi P, Martínez-Lacalle A, Crespo E, et al. · Am J Transplant 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.